por
Gus Iversen, Editor in Chief | May 12, 2025
Ratio Therapeutics has announced plans to build a 65,000-square-foot radiopharmaceutical manufacturing and research facility in Salt Lake City, Utah, aiming to support its growing pipeline of cancer-focused radiopharmaceuticals.
The Boston-based company has partnered with the Medical Innovation Technology Management division of Wasatch Group to develop the site, which will be located within Wasatch’s Medical Innovation Technology Research Campus.
The new facility, slated for completion in the second half of 2027, is designed to enable end-to-end production of radiopharmaceuticals, with an eye toward scaling up for commercial supply. Ratio highlighted the location’s proximity to established suppliers and Salt Lake City’s international airport as key logistical advantages, positioning the company to manage complex radiopharmaceutical supply chains more efficiently.
Ad Statistics
Times Displayed: 118186
Times Visited: 6878 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. [email protected]/+1 (305) 470-8013
Jack Hoppin, Ph.D., chairman and CEO of Ratio, said the move is a strategic step for the company as it advances its candidates through clinical development. “Ratio is excited to partner with Wasatch, who is ambitiously driving our field forward. With our pipeline advancing rapidly, securing a strategic manufacturing footprint is crucial to our long-term vision,” Hoppin said. “This facility not only places us near potential suppliers, such as Nusano, but also provides the infrastructure needed to meet future manufacturing demands at commercial scale.”
Ratio’s new site will be the first tenant in the Medical Innovation Technology Research and Development Park, which Wasatch designed to foster collaboration across the medical sector. Tanner J.M. Bowman, president of MIT Management, said, “Ratio’s cutting-edge work in radiopharmaceuticals perfectly aligns with our vision for this innovation hub. This partnership not only brings high-quality jobs to Salt Lake Valley but also strengthens Utah’s growing reputation as a center for healthcare innovation.”
Ratio’s current development focus includes a FAP-targeted radiotherapeutic expected to enter clinical trials this year.
